Johnson & Johnson (JNJ) stock
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3086% above fair value
$278.70−3.85 (-1.36%)
Close on Nov 17, 2026Market cap $670.92BP/E 42.3Yield 1.84%
Johnson & Johnson ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2014 it was $25.49B, up 24.2% from the year before. The highest annual figure on record is $25.49B in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2014 | Dec 28, 2014 | $25.49B | +24.2% |
| FY2013 | Dec 29, 2013 | $20.52B | +10.2% |
| FY2012 | Dec 30, 2012 | $18.62B | +10.0% |
| FY2011 | Jan 1, 2012 | $16.92B | -18.0% |
| FY2010 | Jan 2, 2011 | $20.64B | +6.6% |
| FY2009 | Jan 3, 2010 | $19.36B | – |
See a number that looks wrong?